-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Impact of Iron Availability on Megakaryopoiesis

Program: Spotlight Sessions
Session: Iron at the Crossroads Between Erythropoiesis and Megakaryopoiesis
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Clinical trials, Translational Research, Clinical Research
Monday, December 9, 2024, 2:45 PM-4:00 PM

Radek C. Skoda, MD

Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

Disclosures: Skoda: Ajax Therapeutics: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria; AOP: Honoraria, Speakers Bureau; Bristol Myers Squibb/Celgene: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Baxalta: Consultancy, Honoraria; Pfizer: Consultancy.

See more of: Iron at the Crossroads Between Erythropoiesis and Megakaryopoiesis
See more of: Spotlight Sessions
<< Previous Presentation | Next Presentation